entrectinib
roche
entrectinib in a cohort of pretreated patients with ntrk-fusion gi cancers. n16. orr 44%. mdor 15 months. well tolerated. no new safety signals. #wcgic2022 
MD de la UN. Especialista en medicina interna, docencia y oncología.